The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
Researchers at St. Jude Children’s Research Hospital report findings from a novel and promising treatment for the uncommon neurological disease.
Utilizing reduced Takumi-shaped DNA nanostructures, researchers create optimal DNA hydrogels with possible biological uses.
According to the researchers, these recurring patterns suggest potential therapeutic targets meant to prevent or slow the progression of cancer.
Rare yet debilitating disorders, Dravet syndrome, and other developing epileptic encephalopathies induce a variety of symptoms in children, such as seizures, intellectual incapacity, and even unexpected death. The majority of cases are brought on by a genetic mutation; variations in the sodium channel gene SCN1A are most frequently the cause […]
With the mechanism now known, scientists are attempting to sabotage the process with chemical and mechanical means to allow antibiotics to function without hindrance.
According to the study, even in the absence of established triggers for these antibodies, such as blood thinners (heparin) or previous vaccinations.
The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]
